FILING ANALYSIS · MONDAY, NOVEMBER 9
AbCellera Biologics Inc. ABCL — 8-K: Results of Operations and Financial Condition
negative
AbCellera's Q3 2026 results show a net loss of $40.8 million, but the company raised $200 million in a common share and pre-funded warrant offering, bringing its available liquidity to approximately $900 million. The positive top-line Phase 2 results for ABCL635 and the addition of new pipeline programs are notable, but the capital raise indicates dilution
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →